Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban tablet
Drug: Lefradafiban double chamber sachet
Drug: Pantoprazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264106

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole ER tablet
Drug: Pramipexole IR tablet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264132

Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin
Drug: Paroxetine

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264184

Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine, low dose
Drug: Cilobradine, high dose
Drug: Itraconazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02264041

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-DK-AH 269 CL, drinking solution
Drug: [14C]-DK-AH 269 CL, solution for infusion

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264028

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban tablet
Drug: Pantoprazole tablet
Device: Lefradafiban double chamber sachet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264119

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WAL2014
Drug: Placebo

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264080

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan low
Drug: Placebo
Drug: Telmisartan high
Drug: Lacidipine high
Drug: Lacidipine low

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 149

Registration Number: NCT02264158

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan conventional tablet
Drug: Telmisartan film coated tablet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02263989

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BEA 2180 BR
Drug: Spiriva
Device: Respimat® A 4
Drug: Methacholine Chloride

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 101

Registration Number: NCT02263976

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy